Jazz Pharmaceuticals Announces Participation at Jefferies Virtual London Healthcare Conference
DUBLIN, Nov. 10, 2020 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the company will webcast its corporate presentation at the following virtual healthcare conference:
- Jefferies Virtual London Healthcare Conference on Tuesday, November 17, 2020 at 1:10 p.m. EST / 6:10 p.m. GMT. Daniel Swisher, president and chief operating officer, will provide an overview of the company and a business and financial update.
A live audio webcast of the presentation may be accessed from the Investors section of the Jazz Pharmaceuticals website at www.jazzpharmaceuticals.com. Please connect to the website prior to the start of the presentation to ensure adequate time for any software downloads that may be necessary to listen to the webcast.
An archive of the webcast will be available following the presentation for at least one week on the Investors section of the company's website at www.jazzpharmaceuticals.com.
About Jazz Pharmaceuticals
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) is a global biopharmaceutical company dedicated to developing and commercializing life-changing medicines that transform the lives of patients with serious diseases — often with limited or no options. We have a diverse portfolio of marketed medicines and novel product candidates, from early- to late-stage development, in key therapeutic areas. Our focus is in neuroscience, including sleep and movement disorders, and in oncology, including hematologic malignancies and solid tumors. We actively explore new options for patients including novel compounds, small molecule advancements, biologics and innovative delivery technologies. Jazz is headquartered in Dublin, Ireland and has employees around the globe, serving patients in more than 90 countries. For more information, please visit www.jazzpharmaceuticals.com and follow @JazzPharma on Twitter.
Jazz Pharmaceuticals Contacts: | |
Investors: | Media: |
View original content to download multimedia:http://www.prnewswire.com/news-releases/jazz-pharmaceuticals-announces-participation-at-jefferies-virtual-london-healthcare-conference-301170204.html
SOURCE Jazz Pharmaceuticals plc

Related Stories
-
Jazz Pharmaceuticals Appoints Jennifer Cook and Mark Smith, M.D. to its Board of Directors
PR Newswire 11/17 07:30 ET -
Jazz Pharmaceuticals Announces Participation at Jefferies Virtual London Healthcare Conference
PR Newswire 11/10 16:05 ET -
Were These Hedge Funds Right About Betting On Jazz Pharmaceuticals Plc (JAZZ)?
Yahoo 11/09 12:34 ET -
Data at ASH 2020 Annual Meeting Highlights Jazz Pharmaceuticals' Commitment to Advancing Hematology/Oncology Research
PR Newswire 11/05 07:30 ET -
Data at ASH 2020 Annual Meeting Highlights Jazz Pharmaceuticals' Commitment to Advancing Hematology/Oncology Research
Yahoo 11/05 07:30 ET -
What We Learned About Jazz Pharmaceuticals' (NASDAQ:JAZZ) CEO Pay
Yahoo 11/04 08:32 ET -
Jazz Pharmaceuticals Up on Third Quarter Earnings Beat
Yahoo 11/03 11:55 ET -
--Analyst Actions: Barclays Adjusts Price Target for Jazz Pharmaceuticals to $233 From $225, Maintains Overweight Rating
MT Newswires 11/03 11:33 ET -
--Analyst Actions: JP Morgan Adjusts Price Target for Jazz Pharmaceuticals to $178 From $175, Maintains Overweight Rating
MT Newswires 11/03 11:32 ET -
--Analyst Actions: Wells Fargo Adjusts Price Target on Jazz Pharmaceuticals to $184 From $171, Reiterates Overweight Rating
MT Newswires 11/03 11:29 ET